Evidence map›Paper›PMID 35724343›Full record

ArticleHuman vaccines & immunotherapeutics2022

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice.

Abenaya Muralidharan, Caroline Gravel, Greg Harris, Anwar M Hashem, Wanyue Zhang, David Safronetz, Gary Van Domselaar, Florian Krammer, Simon Sauve, Michael Rosu-Myles and 3 more

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Abenaya MuralidharanDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Caroline GravelCentre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
Greg HarrisHuman Health Therapeutics (HHT) Research Center, National Research Council of Canada, Ottawa, Canada.
Anwar M HashemVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Wanyue ZhangDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
David SafronetzNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Gary Van DomselaarNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0003-4121-776X
Simon SauveCentre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
Michael Rosu-MylesDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Lisheng WangDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Wangxue ChenHuman Health Therapeutics (HHT) Research Center, National Research Council of Canada, Ottawa, Canada.ORCID 0000-0003-0958-7728
Xuguang LiDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Health Canada · CANational Research Council Canada · CAPublic Health Agency of Canada · CAUniversity of Ottawa · CAIcahn School of Medicine at Mount Sinai · USKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza is a major public health concern causing millions of hospitalizations every year. The current vaccines need annual updating based on prediction of likely strains in the upcoming season. However, mismatches between vaccines and the actual circulating viruses can occur, reducing vaccine effectiveness significantly because of the remarkably high rate of mutation in the viral glycoprotein, hemagglutinin (HA). Clearly, it would be of great interest to determine the potential role of universally conserved epitopes in inducing protective immunity. Here, an antibody against the 14-aa fusion peptide sequence at the

Indexed as

Influenza, HumanInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHumansMicePeptidesAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesPeptidesantibody-dependent cellular cytotoxicity (ADCC)cross-protectionInfluenzaUni-1universal antibody

Identifiers

PMID35724343
PMCPMC9621047
OpenAlexW4283212572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.